The path forward is unclear. With low entry barrier in the industry, whether lalpath will grow at a pace which justifies it’s PE valuation.
Repeating the growth from COVID quarters is not possible.
1 Like
The path forward is unclear. With low entry barrier in the industry, whether lalpath will grow at a pace which justifies it’s PE valuation.
Repeating the growth from COVID quarters is not possible.